ArticleThe Lancet. Rheumatology2020

Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial.

Viola Klück et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.